TeamDrive
RUS

RUSNANO

http://en.rusnano.com/

RUSNANO was founded as a joint stock company in March 2011, through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO is instrumental in realizing government policies for nanoindustry growth, investing in financially effective high-technology projects that guarantee the development of new manufacturing within the Russian Federation. The company invests in nanotechnology companies directly and through investment funds. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. By the moment thanks to RUSNANO’s investments 73 plants and R&D centers are launched in 32 regions of Russia.

Management of the investment assets of RUSNANO are carried out by a limited liability company established in December 2013, RUSNANO Asset Management. Anatoly Chubais is Chairman of its Executive Board.

Media Center

  • 16 January 2018

    The coming of age of gene therapy: A review of the past and path forward

    After three decades of hopes tempered by setbacks, gene therapy—the process of treating a disease by modifying a person’s DNA—is no longer the future of medicine, but is part of the present-day clinical treatment toolkit. The Jan. 12 issue of the journal Science provides an in-depth and timely review of the key developments that have led to several successful gene therapy treatments for patients with serious medical conditions.

  • 16 January 2018

    Russia approves the mechanism for introducing the medicines into circulation

    A draft federal law on the introduction of medicinal products for human use into civil circulation was prepared by the Russian Ministry of Health. The bill proposes to establish a more effective legal regulation of relations associated with the elaboration, application and enforcement of requirements in the area of circulation of medicinal products for human use, namely, by establishing a mechanism for release control of medicines coming into the civil circulation in Russia.

  • 15 January 2018

    Drug discovery IT solutions will reach $5.3 billion globally by 2020

    The latest analysis, Growth Insights – Global Pharmaceutical Drug Discovery IT Solutions Market, Forecast to 2020, by Frost & Sullivan highlights the growing interest in big data analytics and artificial intelligence (AI)-based solutions.

  • 15 January 2018

    Clinical trials of Russian polio vaccine will be completed by mid-2018

    Russian scientists plan to complete the clinical trials of domestically developed inactivated polio vaccine by mid-2018 and are preparing the documents required for the registration of this drug. This was announced by Aidar Ishmukhametov, the Director of M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Products of Russian Academy of Sciences.

Read more